Atenolol, a cardioselective beta blocker, was administered following unsuccessful treatment with propranolol to a male with a significant history of paruresis. During atenolol therapy, the client reported a decrease in ANS symptoms but no increase in ability to urinate in public restrooms. Rationale for use of atenolol is discussed.
Get full access to this article
View all access options for this article.
References
1.
BarlowD. H. (1988) Anxiety and its disorders. New York: Guilford.
2.
HattererJ. A.GormanJ. M.FyerA. J.CampeasR. B.SchneierF. R.HollanderE.PappL. A.LiebowitzM. R. (1990) Pharmacotherapy of four men with paruresis. American Journal of Psychiatry, 147, 109–111.
3.
ZgouridesG. D. (1987) Paruresis: Overview and implications for treatment. Psychological Reports, 60, 1171–1176.
4.
ZgouridesG. D. (1988) Bethanechol chloride as a suggested adjunct to prolonged in vivo exposure therapy in the treatment of paruresis. Perceptual and Motor Skills, 66, 319–322.
5.
ZgouridesG.WarrenR. (1990) Propranolol treatment of paruresis (psychogenic urinary retention): A brief case report. Perceptual and Motor Skills, 71, 885–886.
6.
ZgouridesG.WarrenR.EnglertM. (1990) Use of a portable radio-headset as an adjunct to exposure therapy in treating paruresis. Phobia Practice and Research Journal, 3, 43–44.
